Another study found that conventional mFOLFOX6 chemotherapy combined with cetuximab for KRAS-mutant CRC patients showed was shown to improve efficacy, reduce the overall incidence of adverse events (AEs), improve OS, and extend overall patient survival when adding simvastatin [83]. The gene discussed is KRAS; the disease is colorectal carcinoma.